A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Tyrosine kinase inhibitor therapy with imatinib (IM), dasatinib (DAS), or nilotinib is very effective in chronic-phase chronic myeloid leukemia. Two hundred fifty-three patients with newly diagnosed chronic-phase chronic myeloid leukemia were randomized to IM 400 mg/day or DAS 100 mg/day. The propor...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Radich, Jerald P., Kopecky, Kenneth J., Appelbaum, Frederick R., Kamel-Reid, Suzanne, Stock, Wendy, Malnassy, Greg, Paietta, Elisabeth, Wadleigh, Martha, Larson, Richard A., Emanuel, Peter, Tallman, Martin, Lipton, Jeff, Turner, A. Robert, Deininger, Michael, Druker, Brian J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2012
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3496952/
https://ncbi.nlm.nih.gov/pubmed/22915637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-410688
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы